IDEAYA Biosciences (IDYA) News Today $28.15 -1.31 (-4.45%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Oppenheimer Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA)October 31 at 2:38 AM | americanbankingnews.comAnalysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $55.45October 30 at 2:05 AM | americanbankingnews.comOppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)October 29 at 8:44 PM | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)October 29 at 3:36 PM | markets.businessinsider.comOppenheimer Reaffirms Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)Oppenheimer reissued an "outperform" rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday.October 29 at 12:30 PM | marketbeat.comIDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLCOctober 29 at 4:50 AM | americanbankingnews.comIdeaya Biosciences announces IND clearance for Werner Helicase inhibitorOctober 28 at 2:29 PM | markets.businessinsider.comIDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsOctober 28 at 6:00 AM | prnewswire.comIDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at UBS GroupOctober 28 at 1:39 AM | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Buy" by AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been assigned a consensus rating of "Buy" from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. Fourteen equities research analysts have rated the stock with a buy recommendation and one haOctober 27, 2024 | marketbeat.comOptimistic Buy Rating for IDEAYA Biosciences Amid Promising Drug Development and Strategic PotentialOctober 26, 2024 | markets.businessinsider.comPromising Clinical Data and Strong Safety Profile Support Buy Rating for IDEAYA BiosciencesOctober 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for IDEAYA Biosciences Driven by Promising IDE397 Data and Strong Financial PositionOctober 26, 2024 | markets.businessinsider.comIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024October 25, 2024 | prnewswire.comIdeaya Biosciences initiated with a Buy at UBSOctober 24, 2024 | markets.businessinsider.comLeerink Partnrs Has Bearish Estimate for IDYA Q3 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for IDEAYA Biosciences in a research report issued to clients and investors on Tuesday, October 22nd. Leerink Partnrs analyst A. Berens now forecasts tOctober 24, 2024 | marketbeat.comUBS Group Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA)UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday. They set a "buy" rating and a $50.00 price target for the company.October 24, 2024 | marketbeat.comLogos Global Management LP Acquires New Stake in Bright Minds Biosciences IncOctober 24, 2024 | finance.yahoo.comIDEAYA Biosciences: Promising Prospects for Darovasertib in Uveal Melanoma Neoadjuvant TreatmentOctober 23, 2024 | markets.businessinsider.comIDEAYA Biosciences’ IDE397: Promising Data and Commercial Potential Drive Buy RatingOctober 21, 2024 | markets.businessinsider.comAnalysts Offer Predictions for IDYA FY2024 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Cantor Fitzgerald issued their FY2024 earnings estimates for IDEAYA Biosciences in a report released on Wednesday, October 16th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.26) for theOctober 18, 2024 | marketbeat.comCantor Fitzgerald Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA)Cantor Fitzgerald started coverage on shares of IDEAYA Biosciences in a research note on Tuesday. They issued an "overweight" rating on the stock.October 15, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 3.7% - Here's What HappenedIDEAYA Biosciences (NASDAQ:IDYA) Trading Down 3.7% - What's Next?October 9, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Has $509,000 Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Healthcare of Ontario Pension Plan Trust Fund lessened its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 70.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor ownedOctober 9, 2024 | marketbeat.comAlgert Global LLC Sells 24,193 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Algert Global LLC trimmed its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 65.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,676 shares of the company's stock after selling 24,193 sOctober 8, 2024 | marketbeat.comIDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR SymposiumOctober 4, 2024 | prnewswire.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.2% IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.2%October 3, 2024 | marketbeat.comEnvestnet Asset Management Inc. Raises Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Envestnet Asset Management Inc. grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 24.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,553 shares of the company's stock after acquiring an additioOctober 3, 2024 | marketbeat.comSquarepoint Ops LLC Purchases 56,256 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Squarepoint Ops LLC raised its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 127.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 100,502 shares of the company's stock after purchasing an additional 56,256 shares during the period.October 2, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from BrokeragesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating and one has issued a strong buy ratingOctober 2, 2024 | marketbeat.comBuy Rating on IDEAYA Biosciences Amidst Promising Uveal Melanoma Drug Developments and Strategic Pipeline ExpansionOctober 1, 2024 | markets.businessinsider.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) is Logos Global Management LP's 4th Largest PositionLogos Global Management LP boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 13.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,700,000 shares of the company's stock after purchasingOctober 1, 2024 | marketbeat.comD. E. Shaw & Co. Inc. Has $31.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)D. E. Shaw & Co. Inc. lifted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 34.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 884,538 shares of the company's stock aftSeptember 29, 2024 | marketbeat.comScientech Research LLC Boosts Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Scientech Research LLC raised its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 362.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 27,708 shares of the company's stock after acquiriSeptember 28, 2024 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 27, 2024 | prnewswire.comBuy Rating Affirmed for IDEAYA Biosciences on Strong Darovasertib Efficacy and Favorable FDA Meeting OutcomesSeptember 26, 2024 | markets.businessinsider.comDeerfield Management Company L.P. Series C Sells 533,179 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Deerfield Management Company L.P. Series C lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 20.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,097,113 shares of theSeptember 26, 2024 | marketbeat.comIDEAYA’s rare cancer drug shows promise as company lays out Phase III plansSeptember 24, 2024 | finance.yahoo.comIDEAYA Biosciences (IDYA) Receives a Buy from RBC CapitalSeptember 24, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)September 24, 2024 | markets.businessinsider.comWedbush Cuts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $52.00Wedbush reduced their price target on IDEAYA Biosciences from $54.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday.September 24, 2024 | marketbeat.comIDEAYA Biosciences' (IDYA) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday.September 24, 2024 | marketbeat.comSamlyn Capital LLC Raises Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Samlyn Capital LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 27.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 611,820 shares of the company's stock after buyingSeptember 24, 2024 | marketbeat.comIdeaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer CandidateSeptember 23, 2024 | msn.comIdeaya Biosciences Sees Posisitive Data From Darovasertib TrialSeptember 23, 2024 | marketwatch.comIDEAYA Announces Positive Interim Phase 2 Data For Darovasertib In Neoadjuvant Uveal MelanomaSeptember 23, 2024 | markets.businessinsider.comHighVista Strategies LLC Sells 58,436 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)HighVista Strategies LLC lessened its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 58.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,856 shares of the company's stock afSeptember 23, 2024 | marketbeat.comIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaSeptember 23, 2024 | prnewswire.comIDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024September 22, 2024 | prnewswire.comIdeaya Biosciences Advances Synthetic Lethality With IDE397 SuccessSeptember 20, 2024 | seekingalpha.com Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.310.68▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼195▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalyst Pharmaceuticals News Cue Biopharma News Syros Pharmaceuticals News TherapeuticsMD News Roivant Sciences News Revolution Medicines News Legend Biotech News Intra-Cellular Therapies News Viking Therapeutics News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts